HK inno.N Corporation will be responsible for the manufacture and supply of Tegoprazan, while Dr. Reddy's will handle local clinical development, registration, marketing and sales
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
The renewed commitment will provide continued preventative (prophylactic) treatment to as many as 1,000 people with haemophilia A in locations where there is little to no access to haemophilia treatment
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
The company is preparing the response to the observations, which will be submitted to the USFDA within 15 business days
Pfizer to commercialize NURTEC ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraine, a condition with high unmet need
Takeda and United Nations Global Compact Network of India (UNGCNI) join hands
He was previously working as the CEO of IVD business at Trivitron Healthcare and drove its growth through innovation
Subscribe To Our Newsletter & Stay Updated
